Chronic liver failure

Summary

Chronic liver failure (MONDO:0100193) is a disease and 124 clinical trials. Top therapeutic interventions include phendimetrazine tartrate, tacrolimus anhydrous, and angiotensin ii. A subtype of liver failure — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 124

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	chronic liver failure
Mondo ID	MONDO:0100193
ICD-10-CM	K72.1
ICD-11	282512557
NCIT	C84428
UMLS	C2936476
MedGen	423539
Is cancer (heuristic)	no

Also known as: end stage liver disease · end stage liver disease (decompensated liver disease) · end-stage liver disease · ESLD

Disease family

This is a subtype of liver failure. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › digestive system disorder › hepatobiliary disorder › liver disorder › liver failure › chronic liver failure

Related subtypes (2): infantile liver failure, acute liver failure

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 124.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	92
PHASE1/PHASE2	9
PHASE4	6
PHASE3	5
PHASE1	5
PHASE2	3
EARLY_PHASE1	3
PHASE2/PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04592744	PHASE4	ENROLLING_BY_INVITATION	Angiotensin 2 for AKI After OLT
NCT00163657	PHASE4	COMPLETED	Study of Liver Transplant For End-Stage Liver Disease Caused By Chronic Hepatitis C Infection
NCT00656266	PHASE4	TERMINATED	Trial of Calcineurin Inhibitor-Sparing Immunosuppression Regimen in Pediatric Liver Transplantation
NCT02504138	PHASE4	COMPLETED	A Comparison of Propofol Based Total Intravenous Anesthesia and Desflurane Based Balanced Anesthesia on Hepatic Protection During Living-donor Liver Transplantation
NCT03208127	PHASE4	TERMINATED	DAA Treatment in Donor HCV-positive to Recipient HCV-negative Liver Transplant
NCT04107428	PHASE4	UNKNOWN	Somatostatin in Living Donor Liver Transplantation
NCT00604357	PHASE3	COMPLETED	CNI-free de Novo Protocol in Patients Undergoing Liver Transplantation With Renal Impairment
NCT00687349	PHASE3	COMPLETED	Improving Clinician Communication Skills (ICCS)
NCT01171742	PHASE3	UNKNOWN	Effect of Intermittent Hepatic Inflow Occlusion During Donor Hepatectomy In Living Donor Liver Transplantation
NCT02584283	PHASE3	COMPLETED	Dual Hypothermic Oxygenated Perfusion of DCD Liver Grafts in Preventing Biliary Complications After Transplantation
NCT03109236	PHASE3	UNKNOWN	Autologous Endothelial Progenitor Cell Therapy for Reversal of Liver Cirrhosis
NCT05253287	PHASE2/PHASE3	COMPLETED	Growth Hormone in Decompensated Liver Cirrhosis
NCT02581085	PHASE2	ACTIVE_NOT_RECRUITING	Tocotrienol Against the Progression of End Stage Liver Disease
NCT04496479	PHASE2	RECRUITING	Allogenic Hepatocyte Transplantation Into Periduodenal Lymph Nodes
NCT06823713	PHASE1/PHASE2	RECRUITING	RTX001 Autologous Engineered Macrophages for Liver Cirrhosis
NCT07269041	PHASE1/PHASE2	RECRUITING	Immune Tolerance Induction After Liver Transplantation
NCT00249652	PHASE1/PHASE2	COMPLETED	Transplant and Addiction Project (TAP) - 1
NCT01412593	PHASE1/PHASE2	UNKNOWN	Intra-hepatic Artery Bone Marrow Derived Stem Cells Infusion for the Treatment of Advanced Liver Cirrhosis
NCT01724697	PHASE1/PHASE2	UNKNOWN	Safety and Efficacy of Human Bone Marrow Stem Cells for Treatment of HBV-related Liver Cirrhosis
NCT01728688	PHASE1/PHASE2	UNKNOWN	Safety and Efficacy of Human Autologous Peripheral Blood Stem Cells for Treatment of HBV-related Liver Cirrhosis
NCT01728727	PHASE1/PHASE2	UNKNOWN	Safety and Efficacy of Human Umbilical Cord Derived Mesenchymal Stem Cells for Treatment of HBV-related Liver Cirrhosis
NCT01907074	PHASE2	TERMINATED	Quantitative Liver Function Tests Using Cholates
NCT02166177	PHASE1/PHASE2	COMPLETED	Safety and Efficacy Study of Regulatory T Cell Therapy in Liver Transplant Patients
NCT03089840	PHASE1/PHASE2	COMPLETED	Normothermic Liver Preservation Trial
NCT05727722	PHASE1	RECRUITING	Micro-encapsulated Hepatocyte Intraperitoneal Transplantation in Liver Failure Adults
NCT06455280	PHASE1	RECRUITING	A Study of SIPLIZUMAB in AILD and LT Patients
NCT01711073	PHASE1	UNKNOWN	Mobilization of Stem Cells With G-CSF and Mozobil in Patients With End Stage Liver Disease
NCT02478151	PHASE1	UNKNOWN	Using Ex-vivo Normothermic Machine Perfusion With the Organox Metra™ Device to Store Human Livers for Transplantation
NCT05195125	PHASE1	UNKNOWN	Use of Direct Peritoneal Resuscitation in High-risk Liver Transplant Recipients
NCT00678834	EARLY_PHASE1	COMPLETED	Human Tissue Distribution of Orally Supplemented Natural Vitamin E Tocotrienol
NCT02617498	EARLY_PHASE1	COMPLETED	Spray Diathermy Versus Harmonic Scalpel Technique for Hepatic Parenchymal Transection
NCT03468140	EARLY_PHASE1	WITHDRAWN	Pilot Trial of Eculizumab Therapy to Reduce Preservation Injury in Human Macrosteatotic Liver Transplantation
NCT02699736	Not specified	ENROLLING_BY_INVITATION	EuroSIDA - Clinical and Virological Outcome of European Patients Infected With HIV
NCT03228290	Not specified	RECRUITING	Functional Assessment in Liver Transplantation
NCT03803423	Not specified	RECRUITING	Dissemination of the Donor Application: Utilizing Social Media to Identify Potential Live Organ Donors
NCT03946852	Not specified	NOT_YET_RECRUITING	Abdominal Regional Perfusion in Donation After Cardiac Death for Multi-Organ Transplantation
NCT04037995	Not specified	RECRUITING	Real World Study of End-stage Liver Disease in China
NCT05001009	Not specified	ENROLLING_BY_INVITATION	Goals of Care Conversations Study
NCT05205954	Not specified	RECRUITING	HepHospital: A Pilot Trial of a Hepatology Home Hospital Intervention for Patients With Advanced Liver Disease
NCT05260268	Not specified	RECRUITING	Technology Enabled Strategies to Promote Treatment Adherence in Liver Transplant

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
PHENDIMETRAZINE TARTRATE	4	2
TACROLIMUS ANHYDROUS	4	2
ANGIOTENSIN II	4	1
CYCLOSPORINE	4	1
ECULIZUMAB	4	1
LACTULOSE	4	1
MIDODRINE	4	1
MYCOPHENOLATE MOFETIL	4	1
NOREPINEPHRINE	4	1
SIROLIMUS	4	1
GLUTATHIONE	3	1
SOMATOSTATIN	3	1
TOCOTRIENOL	3	1
SIPLIZUMAB	2	1
SOLIZMESTROCEL	2	1
CHEMBL406352	0	1
CHEMBL4564923	0	1
CHEMBL432	0	1
SCEPTRIN	0	1